Author
Listed:
- Peter C Gøtzsche
- Asbjørn Hróbjartsson
- Helle Krogh Johansen
- Mette T Haahr
- Douglas G Altman
- An-Wen Chan
Abstract
Background: Ghost authorship, the failure to name, as an author, an individual who has made substantial contributions to an article, may result in lack of accountability. The prevalence and nature of ghost authorship in industry-initiated randomised trials is not known. Methods and Findings: We conducted a cohort study comparing protocols and corresponding publications for industry-initiated trials approved by the Scientific-Ethical Committees for Copenhagen and Frederiksberg in 1994–1995. We defined ghost authorship as present if individuals who wrote the trial protocol, performed the statistical analyses, or wrote the manuscript, were not listed as authors of the publication, or as members of a study group or writing committee, or in an acknowledgment. We identified 44 industry-initiated trials. We did not find any trial protocol or publication that stated explicitly that the clinical study report or the manuscript was to be written or was written by the clinical investigators, and none of the protocols stated that clinical investigators were to be involved with data analysis. We found evidence of ghost authorship for 33 trials (75%; 95% confidence interval 60%–87%). The prevalence of ghost authorship was increased to 91% (40 of 44 articles; 95% confidence interval 78%–98%) when we included cases where a person qualifying for authorship was acknowledged rather than appearing as an author. In 31 trials, the ghost authors we identified were statisticians. It is likely that we have overlooked some ghost authors, as we had very limited information to identify the possible omission of other individuals who would have qualified as authors. Conclusions: Ghost authorship in industry-initiated trials is very common. Its prevalence could be considerably reduced, and transparency improved, if existing guidelines were followed, and if protocols were publicly available. Of 44 industry-initiated trials, there was evidence of ghost authorship in 33, increasing to 40 when a person qualifying for authorship was acknowledged rather than appearing as an author. Background.: Original scientific findings are usually published in the form of a “paper”, whether it is actually distributed on paper, or circulated via the internet, as this one is. Papers are normally prepared by a group of researchers who did the research and are then listed at the top of the article. These authors therefore take responsibility for the integrity of the results and interpretation of them. However, many people are worried that sometimes the author list on the paper does not tell the true story of who was involved. In particular, for clinical research, case histories and previous research has suggested that “ghost authorship” is commonplace. Ghost authors are people who were involved in some way in the research study, or writing the paper, but who have been left off the final author list. This might happen because the study “looks” more credible if the true authors (for example, company employees or freelance medical writers) are not revealed. This practice might hide competing interests that readers should be aware of, and has therefore been condemned by academics, groups of editors, and some pharmaceutical companies. Why Was This Study Done?: This group of researchers wanted to get an idea of how often ghost authorship happened in medical research done by companies. Previous studies looking into this used surveys, whereby the researchers would write to one author on each of a group of papers to ask whether anyone else had been involved in the work but who was not listed on the paper. These sorts of studies typically underestimate the rate of ghost authorship, because the main author might not want to admit what had been going on. However, the researchers here managed to get access to trial protocols (documents setting out the plans for future research studies), which gave them a way to investigate ghost authorship. What Did the Researchers Do and Find?: In order to investigate the frequency and type of ghost authorship, these researchers identified every trial which was approved between 1994 and 1995 by the ethics committees of Copenhagen and Frederiksberg in Denmark. Then they winnowed this group down to include only the trials that were sponsored by industry (pharmaceutical companies and others), and only those trials that were finished and published. The protocols for each trial were obtained from the ethics committees and the researchers then matched up each protocol with its corresponding paper. Then, they compared names which appeared in the protocol against names appearing on the eventual paper, either on the author list or acknowledged elsewhere in the paper as being involved. The researchers ended up studying 44 trials. For 31 of these (75% of them) they found some evidence of ghost authorship, in that people were identified as having written the protocol or who had been involved in doing statistical analyses or writing the manuscript, but did not end up listed in the manuscript. If the definition of authorship was made narrower, and “ghost authorship” included people qualifying for authorship who were mentioned in the acknowledgements but not the author list, the researchers' estimate went up to 91%, that is 40 of the 44 trials. For most of the trials with missing authors, the ghost was a statistician (the person who analyzes the trial data). What Do These Findings Mean?: In this study, the researchers found that ghost authorship was very common in papers published in medical journals (this study covered a broad range of peer-reviewed journals in many medical disciplines). The method used in this paper seems more reliable than using surveys to work out how often ghost authorship happens. The researchers aimed to define authorship using the policies set out by a group called the International Committee of Medical Journal Editors (ICMJE), and the findings here suggest that the ICMJE's standards for authorship are very often ignored. This means that people who read the published paper cannot always accurately judge or trust the information presented within it, and competing interests may be hidden. The researchers here suggest that protocols should be made publicly available so that everyone can see what trials are planned and who is involved in conducting them. The findings also suggest that journals should not only list the authors of each paper but describe what each author has done, so that the published information accurately reflects what has been carried out. Additional Information.: Please access these Web sites via the online version of this summary at http://dx.doi.org/10.1371/journal.pmed.0040019.
Suggested Citation
Peter C Gøtzsche & Asbjørn Hróbjartsson & Helle Krogh Johansen & Mette T Haahr & Douglas G Altman & An-Wen Chan, 2007.
"Ghost Authorship in Industry-Initiated Randomised Trials,"
PLOS Medicine, Public Library of Science, vol. 4(1), pages 1-6, January.
Handle:
RePEc:plo:pmed00:0040019
DOI: 10.1371/journal.pmed.0040019
Download full text from publisher
Citations
Citations are extracted by the
CitEc Project, subscribe to its
RSS feed for this item.
Cited by:
- Nadine Desrochers & Adèle Paul‐Hus & Jen Pecoskie, 2017.
"Five decades of gratitude: A meta‐synthesis of acknowledgments research,"
Journal of the Association for Information Science & Technology, Association for Information Science & Technology, vol. 68(12), pages 2821-2833, December.
- Jonathan M. Levitt & Mike Thelwall, 2016.
"Long term productivity and collaboration in information science,"
Scientometrics, Springer;Akadémiai Kiadó, vol. 108(3), pages 1103-1117, September.
- John M McPartland, 2009.
"Obesity, the Endocannabinoid System, and Bias Arising from Pharmaceutical Sponsorship,"
PLOS ONE, Public Library of Science, vol. 4(3), pages 1-7, March.
- Thelwall, Mike & Sud, Pardeep, 2016.
"National, disciplinary and temporal variations in the extent to which articles with more authors have more impact: Evidence from a geometric field normalised citation indicator,"
Journal of Informetrics, Elsevier, vol. 10(1), pages 48-61.
- Salandra, Rossella, 2018.
"Knowledge dissemination in clinical trials: Exploring influences of institutional support and type of innovation on selective reporting,"
Research Policy, Elsevier, vol. 47(7), pages 1215-1228.
- Unruh, Lynn & Rice, Thomas & Rosenau, Pauline Vaillancourt & Barnes, Andrew J., 2016.
"The 2013 cholesterol guideline controversy: Would better evidence prevent pharmaceuticalization?,"
Health Policy, Elsevier, vol. 120(7), pages 797-808.
- Sismondo, Sergio, 2008.
"How pharmaceutical industry funding affects trial outcomes: Causal structures and responses,"
Social Science & Medicine, Elsevier, vol. 66(9), pages 1909-1914, May.
- John P A Ioannidis, 2008.
"Measuring Co-Authorship and Networking-Adjusted Scientific Impact,"
PLOS ONE, Public Library of Science, vol. 3(7), pages 1-8, July.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pmed00:0040019. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosmedicine (email available below). General contact details of provider: https://journals.plos.org/plosmedicine/ .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.